Join-point regression analysis of the statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

Comparison of different fibre release and placement options. by Adrianne L. Jenner (11133854)

Subjects:

Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review by Cayley Russell (8087372)

“…Among other barriers, daily dosing requirements hinder treatment continuity post-release. Extended-release buprenorphine (XR-BUP) may therefore be beneficial. …”

Effect of extended-release buprenorphine (1 mg/kg SC) on tactile hypersensitivity in a rat model of inflammation. by Christina M. Larson (18196213)

“…<p>The mechanical nociceptive threshold is transiently changed by extended-release buprenorphine. Initial hypersensitivity tested at time point 0 was compared to time points following administration of extended-release buprenorphine (Bupe ER). …”

Increasing gaps and decreasing returns attenuate spending effects. by William Minozzi (8564712)

Decreased recovery times were observed after repeated handling and anesthesia sessions. by Lingzhi Wang (114519)

DataSheet1_Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.zip by Chen Qi Zhang (12398296)

“…<p>Purpose: A novel once-daily divalproex-extended release (ER) dose formulation has been developed; this formulation prolongs the therapeutic serum levels of the drug, compared with the twice-daily conventional divalproex-delayed release (DR) formulation. …”

Hyperplasia of the suboccipital muscles significantly increased intracranial pressure. by Chan Li (433717)

Subjects:

Total tau levels are significantly decreased in the healthy older brains compared to the younger brains. by Shreyasi Chatterjee (3531506)

General increases to network connectivity and payoff observed as prioritisation for private information is increased in networks, along with potential decreases to recovery ratios. by Adam Lee Miles (14123916)

Effect of extended-release buprenorphine (1 mg/kg SC) as compared to saline control on tactile hypersensitivity in a model of inflammatory hypersensitivity in rats. by Christina M. Larson (18196213)

“…A) In both male and female subjects analyzed together, there is significant elevation of mechanical thresholds for rats treated with extended-release buprenorphine (Bupe ER) as compared to rats treated with saline following induction of inflammation via intraplantar CFA. …”

Join-point regression analysis of the statistically significant linear increase in use of anxiolytics, psychostimulants and noot ropic drugs, sedatives and hypnotics, gabapentinoid... by Jelena Filimonovic (22305307)

Summary of significance levels for comparison of surgical segment ROM between different test groups. by Jia Zhu (135506)

Subjects:

The observed MRM reactions. by Ewa Paszkowska (21246702)

Effect of extended-release buprenorphine (1 mg/kg, SC) as compared to saline control on tactile hypersensitivity in an incisional model of post-operative pain in the rat. by Christina M. Larson (18196213)

“…<p>The mechanical nociceptive thresholds in subjects given extended-release buprenorphine are not significantly different from those in subjects given saline. …”

CFU-Mk is significantly decreased by GATA1s overexpression in <i>GATA1s</i> strains. by Shiori Matsuo (10492159)

Knockout of <i>CLTC</i> caused a decrease infection of SFTSV. by Tiezhu Liu (4175812)

<b>Extended Osteoarthritis Pain Relief with Neosaxitoxin using Alginate-core Polymeric Microparticles</b> by Hengli Zhang (21602333)

Supplementary Material for: Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Months Naturalistic Study by Brenna I.H. (19773549)

“…ABSTRACT Introduction The treatment efficacy of extended-release naltrexone (XR-NTX) for opioid use disorder (OUD) has been demonstrated in several studies, but not in naturalistic settings where opioid agonist treatment (OAT) is freely accessible. …”

Table 1_Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia.docx by Zheng Lan (21451100)

“…Participants were randomized (1:1) to receive either paliperidone extended-release (ER) tablets (titrated 3–12 mg/day) or PP1M (3–9 mg monthly). …”